Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Seized shares of TGK-2 were transferred under the control of Gazprom Energoholding

10/25/23 TGKB

En+ Group reported for 9 months of 2023 by RAS

10/25/23 ENPG

Sovcomflot reports for 9 months of 2023 by RAS

10/25/23 FLOT

Fesco intends to replenish its fleet through M&A deals

10/25/23 FESH

Fesco received an ice-class container ship

10/25/23 FESH

Ashinskiy Metallurgical Plant reported for 9 months of 2023 by RAS

10/25/23 AMEZ

Saratovenergo reported for 9 months of 2023 by RAS

10/25/23 SARE

Boeing reported for 9 months of 2023

10/25/23 BA

General Dynamics reported for 9 months of 2023

10/25/23 GD

SberMarket expanded the geography of delivery from restaurants

10/25/23 SBER